Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
General Drug Use-Results Survey of TIBSOVO in IDH1-mutated nonresectable biliary tract cancer (GENTIANA)
jRCT2031260232Recruiting
- Sponsor
- Servier
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ivosidenib in biliary cancer, sponsored by Servier. Primary endpoint: Incidence of Guillain-Barré syndrome as adverse event (AE) and adverse drug reaction (ADR). Started Jul 2026; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCT2031260232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260232.